ClinicalTrials.gg
TerminatedNCT07157254AuroraUpdated Nov 3, 2026

A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)

A Phase 2 interventional study of No intervention and GTX-102 in Angelman Syndrome, sponsored by Ultragenyx Pharmaceutical Inc. Terminated at 21 sites in 8 countries. Open to participants aged 1 Year to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Ultragenyx Pharmaceutical Inc · Phase 2, Interventional, and Treatment

Why this study was terminated
Lack of efficacy
Updated Nov 3, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
1 Year to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Angelman Syndrome with a site in United States — 6 open to participants now, 10 under way, 3 of them phase 3. Angelman Syndrome · United States.

Enrollment
16th of 24
55 · median 73
Started
2025
with 2 others
Phase 2
3 of 33
none open now
Registered
29th of 33
by date
Lead sponsor
4 of 33
Ultragenyx Pharmaceutical Inc

Among the 33 studies in Angelman Syndrome with a site in United States, this one is the 16th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2025, is one of 3 in phase 2, and was the 29th registered.

Angelman Syndrome

52 studies on the registry are indexed under Angelman Syndrome; 16 are open to participants now.

Browse Angelman Syndrome studies →

Open to participants now

6 of the 33 studies in Angelman Syndrome with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Angelman Syndrome studies recruiting now, 6 (43%) set no upper age limit and 7 (50%) stop at 75 or younger; 14 take children under 18; none take healthy volunteers.

This study: 1 Year to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Angelman Syndrome with a site in United States, or all of them as a file.
02

Study summary

The main goal of the study is to evaluate the safety and efficacy of GTX-102 in participants with Angelman syndrome.

Read the detailed description

This basket study is designed to evaluate safety and efficacy of GTX-102 in participants with Angelman syndrome across genotypes and age groups. The study consists of subprotocols A, B, C and D. All subprotocols are open-label and follow the same design which includes a Screening, Loading and Maintenance period. Subprotocols A, B and C are single arm only. In subprotocol D, participants are randomized 2:1 to a GTX-102 group or a No Treatment group. The No Treatment group follows the same schedule of events as all other groups after completion of the No Treatment period. Participants from all the subprotocols have the option to continue treatment in a long-term extension study following their end of study visit.

03

Conditions studied

  • Angelman Syndrome

Browse trials for

Keywords

  • Angelman Syndrome
04

Who can participate

Ages eligible
1 Year to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed from parent(s) or legal guardian(s)
  2. Males and females of the following ages and genotypes at time of informed consent:

    1. Subprotocol A: ≥ 1 to \< 4 years of age with a genetically confirmed diagnosis of deletion-type Angelman syndrome
    2. Subprotocol B: ≥ 4 to \< 18 years of age with a genetically confirmed diagnosis of UPD/ICD Angelman syndrome
    3. Subprotocol C: ≥ 18 to \< 65 years of age with a genetically confirmed diagnosis of Angelman syndrome, any genotype
    4. Subprotocol D: ≥ 4 to \< 18 years of age with a genetically confirmed diagnosis of mutation-type Angelman syndrome
  3. Weight ≥ 8 kg at Screening Visit
  4. count, / international normalized ratio, and partial thromboplastin time \< 1.5x the and platelets > 75,000 cells/mm3 at the Screening Visit
  5. Willing and able to comply with scheduled visits, drug administration plan, laboratory tests, and all study procedures, including lumbar puncture (LP) procedure, magnetic resonance imaging (MRI) and tolerating anesthesia without intubation
  6. From the time of informed consent through to at least 6 months after the final dose of GTX-102, females of who are sexually active must use highly effective or abstinence. Males are able to participate if they agree to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods during the study and for at least 3 months after the final dose of GTX-102

Exclusion criteria

Exclusion Criteria:

  1. Any change in medications or diet/supplements intended to treat symptoms of Angelman Syndrome (eg, sleeping aids, antiseizure medications, supplements, dietary change including ketogenic or low-glycemic index diet, other) within the month prior to the Screening Visit (excluding weight-based adjustments)
  2. Any condition that creates an increased risk of unsuccessful lumbar puncture
  3. Current or expected concomitant use of drugs that increase the risk of bleeding (eg, heparin, low molecular weight heparin, inhibitors)
  4. Known to GTX-102 or its or required premedication that, in the judgment of the Investigator, places the subject at increased risk for adverse effects
  5. Presence or history of any condition, lab abnormality, or infection that, in the judgment of the Investigator, would interfere with study participation, pose undue safety risk, or would confound interpretation of results
  6. Pregnant or breastfeeding or planning to become pregnant (self or partner) at any time during the study
  7. Use of any product or investigational medical device within 6 months or 5 half-lives prior to the Screening Visit, or any prior use of gene therapy or an ASO regardless of length of time since last use
  8. Concurrent participation in any interventional study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Subprotocol A GTX-102

    Participants with deletion-type Angelman syndrome, ≥1 to \<4 years of age will receive increasing doses of GTX-102 via intrathecal (IT) injection until the target dose is achieved. Dosing occurs every 3 months (Q3M) thereafter.

    Drug: GTX-102

  • Experimental
    Subprotocol B GTX-102

    Participants with paternal uniparental disomy (UPD)/imprinting center defect (ICD) Angelman syndrome, ≥4 to \<18 years of age will receive increasing doses of GTX-102 via IT injection until the target dose is achieved. Dosing occurs Q3M thereafter.

    Drug: GTX-102

  • Experimental
    Subprotocol C GTX-102

    Participants with all genotypes of Angelman syndrome, ≥18 to \<65 years of age will receive increasing doses of GTX-102 via IT injection until the target dose is achieved. Dosing occurs Q3M thereafter.

    Drug: GTX-102

  • Experimental
    Subprotocol D GTX-102

    Participants with mutation-type Angelman syndrome, ≥4 to \<18 years of age will receive increasing doses of GTX-102 via IT injection until the target dose is achieved. Dosing occurs Q3M thereafter.

    Drug: GTX-102

  • Experimental
    Subprotocol D No Intervention then GTX-102

    Participants with mutation-type Angelman syndrome, ≥4 to \<18 years of age will receive no treatment during the initial period. At the end of the no treatment period, participants will receive increasing doses of GTX-102 via IT injection until the target dose is achieved. Dosing occurs Q3M thereafter.

    Other: No intervention · Drug: GTX-102

Interventions

  • OtherNo intervention

    During the no treatment period participants do not receive any study drug

  • antisense oligonucleotide

    Also known as: apazunersen

06

What researchers measure

Primary outcomes

  1. Subprotocol A/B/C/D: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Severe Events, and Events Related to Investigational Product, Procedure, and Premedication

    Time frame: Up to Day 506

  2. Subprotocol A Only: Bayley-4 Cognitive Without Caregiver Input Raw Score Change from Baseline at Day 338

    Time frame: Baseline, Day 338

  3. Subprotocol B/D Only: Multidomain Responder Index (MDRI) Net Response at Day 338

    The following assessments will be included to calculate the MDRI net response: Bayley-4 Cognitive and Receptive Communication, Aberrant Behavior Checklist- Community (ABC-C) Hyperactivity/Noncompliance (H/N), Angelman Severity Assessment (ASA) Sleep, ASA Gross Motor. For each assessment a meaningful score difference (MSD) is defined. A single net response score per participant will be derived accordingly, and a summary measure of net response will then be calculated across all participants.

    Time frame: Baseline, Day 338

  4. Subprotocol C Only: MDRI Net Response at Day 338

    The following assessments will be included to calculate the MDRI net response: Vineland-3 Expressive and Receptive Communication, ABC-C Irritability, ASA Gross Motor. For each assessment a meaningful score difference (MSD) is defined. A single net response score per participant will be derived accordingly, and a summary measure of net response will then be calculated across all participants.

    Time frame: Baseline, Day 338

Secondary outcomes

  1. Subprotocol A/B/D Only: Change From Baseline at Day 338 in Bayley-4 Receptive Communication Raw Score

    Time frame: Baseline, Day 338

  2. Subprotocol A/B/D Only: Change From Baseline at Day 338 in Bayley-4 Gross Motor Raw Score

    Time frame: Baseline, Day 338

  3. Subprotocol B/D Only: Change From Baseline at Day 338 in Bayley-4 Cognitive Raw Score

    Time frame: Baseline, Day 338

  4. Subprotocol B/C/D Only: Change From Baseline at Day 338 in Vineland-3 Receptive Communication Raw Score

    Time frame: Baseline, Day 338

  5. Subprotocol B/C/D Only: Change From Baseline at Day 338 in Vineland-3 Expressive Communication Raw Score

    Time frame: Baseline, Day 338

  6. Subprotocol B/D: Change From Baseline at Day 338 in Aberrant Behavior Checklist-Community (ABC-C) Hyperactivity/Noncompliance Raw Score

    Time frame: Baseline, Day 338

  7. Subprotocol B/D Only: Change From Baseline at Day 338 in Angelman Severity Assessment (ASA) Sleep Rating

    Time frame: Baseline, Day 338

  8. Subprotocol B/C/D Only: Change From Baseline at Day 338 in ASA Gross Motor Rating

    Time frame: Baseline, Day 338

  9. Subprotocol C Only: Change From Baseline at Day 338 in ABC-C Irritability Raw Score

    Time frame: Baseline, Day 338

07

Study locations

21 sites
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Kennedy Kreiger Institute
    Baltimore, Maryland 21205, United States
  • Clinical Trial Site
    Kansas City, Missouri 64108, United States
  • Rare Disease Research
    Hillsborough, North Carolina 27278, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • UT Health Austin
    Austin, Texas 78723, United States
  • Carum Research Inc.
    Dallas, Texas 75243, United States
  • Hospital Universitario Austral
    Pilar, Buenos Aires, Argentina
  • Hospital de Crianças César Pernetta e Hospital Pequeno Príncipe
    Curitiba, Paraná, Brazil
  • Casa dos Raros
    Santa Cecília, Porto Alegre, Brazil
  • Hopital de la Timone
    Marseille, France
  • Necker-Enfants Malades Hospital
    Paris, France
  • Sheba Medical Center
    Ramat Gan, Israel
  • Azienda Ospedaliera Universitaria Meyer IRCCS
    Florence, Italy
  • Fondazione IRCCS Istituto Neurologico C. Besta
    Milan, Italy
  • Clinical Trial Site
    Rome, Italy
  • Hospital de Santa Maria
    Lisbon, Portugal
  • Hospital Santa Joao
    Porto, Portugal
  • Clinical Trial Site
    London, United Kingdom
  • University of Oxford
    Oxford, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2025 to primary completion in Oct 2026, 12 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Jan 2030 → Oct 2026 and completion Jan 2030 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2025
First posted
Sep 5, 2025
StartActual
Oct 13, 2025
Primary completionActual
Oct 30, 2026was Jan 2030
CompletionActual
Oct 30, 2026was Jan 2030
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Lack of efficacy
changed Nov 3, 2026
Primary completion
Jan 2030→Oct 30, 2026 (actual)
Nov 3, 2026
Study completion
Jan 2030→Oct 30, 2026 (actual)
Nov 3, 2026
Enrollment
60 (estimated)→55 (actual)
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Active, not recruiting→Terminated
    Why stopped Lack of efficacy
    Primary completion Jan 2030→Oct 30, 2026 (now actual)
    Study completion Jan 2030→Oct 30, 2026 (now actual)
    Enrollment 60 (estimated)→55 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07157254
Responsible party
Sponsor
First posted
Sep 5, 2025
Start date
Oct 13, 2025
Primary completion
Oct 30, 2026
Completion
Oct 30, 2026
Last update
Nov 3, 2026

Study contacts

Medical Director
study director · Ultragenyx Pharmaceutical Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apazunersen sodium

Start the discussion